Effect of Aromatherapy in CIPN and Fatigue

Phase 3

Recruiting

• Conditions: Condition 1: Drug-induced polyneuropathy. Condition 2: Neoplastic (malignant) related fatigue.; Neoplastic (malignant) related fatigue; G62.0; R53.0

• Registration Number: IRCT20150919024080N19
• Lead Sponsor: Khoram-Abad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 12 July 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

The patient should be between 18 and 80 years old
Have at least one paraesthesia point (based on NRS)
More than 10,000 platelets per cubic millimeter of blood
No severe inflammatory lesions, itching or sores on the hands or feet
The patient must be in stage II or III cancer
Has received at least one session of chemotherapy and is scheduled to receive at least three more sessions within the next month
Existence of fatigue resistant to common treatments
If a specific cause for fatigue, such as anemia, insomnia, depression, or hypercalcemia, is identified, it should be treated first.
No history of peripheral neuropathy for any cause including diabetes mellitus, autoimmune disease, AIDS or previous chemotherapy
Patients with the infection are first treated with oral or intravenous antibiotics
No known mental illness
Ability to communicate and make telephone calls in Persian
After standardizing the fatigue score in the range of 0-100 people with a fatigue score above 30 and a pain score of 3 enter the study
Patient consent to participate in the study
No spread of metastasis to distant and vital organs such as brain and lymph nodes
Inclusion criteria for family caregiver: having a spouse or child relationship with the patient, experience of caring and following the patient for at least one month and willingness to participate in the study

Exclusion Criteria

Deep vein thrombosis
Perform Aromatherapy-Massage for the past month
Dose reduction or discontinuation of medications
Allergy to lavender, chamomile and mint oils
Acute infections require oral or intravenous antibiotics or antiviral and antifungal drugs.
Drug therapy during the study to prevent or treat neuropathy
Existence of coagulation problems or taking anticoagulants
haemorrhage
Pregnancy
Soft tissue infection
Oncological emergencies (such as Tumor Lysis Syndrome)
Participate in other rehabilitation programs, meditation and hydrotherapy, etc. while studying
Exclusion criteria for family caregiver: change the role of family caregiver and transfer his/her role to other family members during the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
eropathic Pain. Timepoint: Before, 14 and 28 days after the start of the intervention. Method of measurement: DN4 questionnaire.;Fatigue. Timepoint: Before, 14 and 28 days after the start of the intervention. Method of measurement: CFS questionnaire.